Other News

Boston Scientific presents 3 year DES MAJESTIC data

Boston Scientific shared the 3-year MAJESTIC DES data online at CardioVascular and Interventional Radiology MAJESTIC 3-Year Data Published for Boston Scientific’s Eluvia DES, by Endovascular Today October 11, 2017—The 3-year results of the MAJESTIC first-in-human study of the Eluvia paclitaxel-eluting vascular stent system (Boston Scientific) for treating femoropopliteal artery lesions were published […]

Endologix, Inc. to Announce Third Quarter 2017 Financial Results on November 7, 2017

IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the third quarter of fiscal year 2017 after the market close on Tuesday, November 7, 2017. The Company’s management will host a conference call at 4:30 […]

Elixir Medical Corporation to Unveil Game-Changing DynamXTM Metallic Stent at the 29th Transcatheter Cardiovascular Therapeutics Conference

MILPITAS, Calif.–(BUSINESS WIRE)–Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling technologies designed to mimic the normal arterial function after cardiovascular and peripheral vascular disease intervention, announced today it will unveil a game-changing metallic drug eluting stent (DES) platform at this year’s Transcatheter Cardiovascular Therapeutics (TCT) conference […]

Silk Road Medical Appoints World Class Stroke Prevention Champion to Serve as Vice President, Medical Affairs and Professional Education

SUNNYVALE, Calif., Oct. 11, 2017 /PRNewswire/ — Silk Road Medical, Inc., a company dedicated to preventing the devastating burden of stroke through surgical innovation, announces the appointment of Tammy Leitsinger to the position of Vice President, Medial Affairs and Professional Education. In this new role, Tammy will further develop and refine global, peer-to-peer TCAR […]

CryoLife Announces Definitive Agreement to Acquire JOTEC

ATLANTA, Oct. 10, 2017 /PRNewswire/ — CryoLife, Inc. (“CryoLife”; NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it has entered into a definitive agreement to acquire JOTEC AG (“JOTEC”).  JOTEC is a German-based, privately-held developer of technologically differentiated endovascular stent grafts, […]

InspireMD Announces The Start Of Patient Enrollment In An Investigator Initiated Trial Of Cguard EPS In Russia

TEL AVIV, ISRAEL–(Marketwired – October 09, 2017) – InspireMD, Inc. (NYSE American: NSPR) (NYSE MKT: NSPR), a leader in Embolic Prevention Systems (EPS) / thrombus management technologies and neurovascular devices, today announced the start of patient enrollment in an investigator initiated trial in Russia, entitled: Independent Randomized Trial in Carotid Artery Revascularization Comparing […]

The Ethical Quandary of LVAD Disconnection

By Ken Dropiewski, Prime-Core Executive Search (ken@prime-core.com) New research brings to light a question of ethics when it comes to the deactivation of a left ventricular assist device (LVAD). Concerns differ significantly between cardiologists, hospice, and palliative medicine clinicians. This has lead to inconsistent and confusing end-of-life care for some […]

HeartStitch® GmbH Announces NobleStitch™ EL Closure Data Compared to Published PFO Clinical Trials “RESPECT” and “CLOSURE” in New England Journal of Medicine

FRANKFURT, Germany, Oct. 6, 2017 /PRNewswire/ — Prof. Dr. Achille Gaspardone, Director of Cardiology at Hospital of Sant’Eugenio (Rome, Italy) presented a comprehensive report on closure of PFO (Patent Foramen Ovale) utilizing the NobleStitch™ EL suture based closure system at the CSI-UCSF meeting on Congenital Structural Interventions in San Francisco.  The NobleStitch™ EL, […]

BIOTRONIK Announces First Enrollments to BIOVITESSE Trial

(PresseBox) – BIOTRONIK has announced the start of enrollment of a coronary stent trial aiming at assessing the safety and clinical performance of a new coronary stent in de novo coronary artery lesions. On September 28, first Dr. Marco Moccetti, Cardiocentro Ticino, Lugano, Switzerland, and later on the same day Dr. Lorenz Raeber, University […]